Regionally specific effects of haloperidol and clozapine on dopamine reuptake in the striatum

Neuroscience Letters

Volumn 228, Issue 2, 1997, Pages 119-122

  Rothblat, David S ^a   Schneider, J S ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Electrochemistry; Neuroleptics; Tardive dyskinesia

Indexed keywords

CLOZAPINE; DOPAMINE; DOPAMINE RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DRUG ABSORPTION; DRUG BINDING; DRUG BRAIN LEVEL; DRUG MECHANISM; DRUG RECEPTOR BINDING; ELECTROCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SENSORIMOTOR FUNCTION; SIDE EFFECT;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; ELECTROPHYSIOLOGY; HALOPERIDOL; MALE; MICROELECTRODES; MICROINJECTIONS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030789063     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(97)00377-7     Document Type: Article

References (24)

1. Bardgett M.E., Wrona C.T., Newcomer J.W., Csernansky J.G. Subcortical excitatory amino acid levels after acute and subchronic administration of typical and atypical neuroleptics. Eur. J. Pharmacol. 230:1993;245-250.
2. Bouthenet M.-L., Souil E., Martres M.-P., Sokoloff P., Giros B., Schwartz J.-C. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res. 564:1991;203-219.
3. Boyson S.J., McGonigle P., Luthin G.R., Wolfe B.B., Molinoff P.B. Effects of chronic administration of neuroleptic and anticholinergic agents on densities of D2 dopamine and muscarinic cholinergic receptors in rat striatum. J. Pharmacol. Exp. Ther. 244:1988;987-993.
4. Cass W.A., Gerhardt G.A. Direct in vivo evidence that D2 dopamine receptors can modulate dopamine uptake. Neurosci. Lett. 176:1994;259-263.
5. Cass W.A., Gerhardt G.A., Zhung Z., Ovadia A., Gash D.M. Increased dopamine clearance in the non-lesioned striatum of rhesus monkeys with unilateral 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) striatal lesions. Neurosci. Lett. 185:1995;52-55.
6. Chiodo L.A., Bunney B.S. Typical and atypical neuroleptics: differential effects of chronic administration of the activity of A9 and A10 midbrain dopaminergic neurons. J. Neurosci. 3:1983;1607-1619.
7. Gainetdinov R.R., Grekhova T.V., Sotnikova T.D., Rayevsky K.S. Dopamine D2 and D3 receptor preferring antagonists differentially affect striatal dopamine release and metabolism in conscious rats. Eur. J. Pharmacol. 261:1994;327-331.
8. Ichikawa J., Meltzer H.Y. Differential effects of repeated treatment with haloperidol and clozapine on dopamine release and metabolism in the striatum and the nucleus accumbens. J. Pharmacol. Exp. Ther. 256:1991;348-357.
9. Innernizzi R., Pozi L., Samanin R. Further studies on the effects of chronic clozapine on regional extracellular dopamine levels in the brain of conscious rats. Brain Res. 670:1995;165-168.
10. Jeste D.V., Lohr J.B., Manley M. Study of neuropathological changes in the striatum following 4, 8 and 12 months of treatment with fluphenazine in rats. Psychopharmacology. 106:1992;154-160.
11. Kerkerian L., Dusticier N., Nieoullon A. Modulatory effect of dopamine on high-affinity glutamate uptake in the rat striatum. J. Neurochem. 48:1987;1301-1306.
12. Knapp A.G., Dowling J.E. Dopamine enhances excitatory amino acid gated conductances in cultured retinal horizontal cells. Nature. 325:1987;437-439.
13. Lidsky T.I., Yablonsky-Alter E., Banerjee S.P. Anti-glutamatergic effects of clozapine. Neurosci. Lett. 163:1993;155-158.
14. Meiergerd S.M., Patterson T.A., Schenk J.O. D2 receptors may modulate the function of the striatal transporter for dopamine: kinetic evidence from studies in vitro and in vivo. J. Neurochem. 61:1993;764-767.
15. Mercugliano M., Chesselet M.-F. Clozapine decreases enkephalin mRNA in rat striatum. Neurosci. Lett. 136:1992;10-14.
16. Meshul C.K., Stallbaumer R.K., Taylor B., Janowsky A. Haloperidol-induced morphological changes in striatum are associated with glutamate synapses. Brain Res. 648:1994;181-195.
17. Miller R., Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol. Psychiatry. 34:1993;713-738.
18. Moghaddam B., Bunney B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J. Neurochem. 54:1990;1755-1760.
19. See R.E., Lynch A.M., Aravagiri M., Nemeroff C.B., Owens M.J. Chronic haloperidol-induced changes in regional dopamine release and metabolism and neurotensin content in rats. Brain Res. 704:1995;202-209.
20. See R.E., Lynch A.M., Sorg B.A. Subchronic administration of clozapine, but not haloperidol or metoclopramide, decreases dopamine D2 receptor messenger RNA levels in the nucleus accumbens and the caudate-putamen in rats. Neuroscience. 72:1996;99-104.
21. Seeman P. Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology. 7:1992;261-284.
22. Sokoloff P., Giros B., Martres M.-P., Bouthenet M.-L., Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 347:1990;146-151.
23. White F.J., Wang R.Y. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science. 221:1983;1054-1057.
24. Zahniser N.R., Larson G.A., Gerhardt G.A. Dopamine clearance rate in the rat striatum effects of uptake inhibitors and dopamine concentration. Soc. Neurosci. Abstr. 22:1996;1577.